ARTICLE | Clinical News
SB-509: Phase IIb started
January 18, 2010 8:00 AM UTC
Sangamo began a double-blind, placebo-controlled Phase IIb (SB-509-901) trial to evaluate intramuscular injections of SB-509 in 150 patients. The Juvenile Diabetes Research Foundation International (J...